Overview

A Study to Investigate the Potential Drug Interactions Between ALXN2080 and Rosuvastatin and Metformin in Healthy Adult Participants

Status:
Completed

Trial end date:
2024-02-05

Target enrollment:

Participant gender:

Summary

The primary objectives of this study are to determine the effect of multiple doses of ALXN2080 on the single-dose PK of rosuvastatin and to determine the effect of multiple doses of ALXN2080 on the single-dose PK of metformin.

Phase:

Phase 1

Details

Lead Sponsor:

Alexion Pharmaceuticals, Inc.

Treatments:

Metformin
Rosuvastatin Calcium